

ASX Announcement and Media Release

19 November 2003

SciGen Limited

RESULTS OF ANNUAL GENERAL MEETING

At the Company's AGM held yesterday, all resolutions were passed by shareholders. Details of submitted proxies are as follows:

Resolution No	Votes cast	Votes for	Votes against	Abstain
1	71,978,359	71,959,100	19,259	-
2	72,015,173	71,857,746	157,427	-
3	72,170,839	70,896,295	1,274,544	-
4	72,171,989	71,074,463	1,097,526	-
5	72,172,996	71,135,273	1,037,723	-
6	72,159,814	71,111,025	1,048,789	-
7	72,001,243	66,481,162	5,520,081	-
8	70,993,130	68,992,551	2,000,579	-
9	71,935,292	68,612,716	3,322,576	-
10	71,318,098	66,419,170	4,898,928	-

About SciGen

SciGen Ltd is registering a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singaporean biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines.

=====ENDS=====

Media enquiries

Mark Compton
Managing Director & CEO
Telephone: +61 2 9234 1700

Web: www.scigen.com.au